LLY
Eli Lilly and Company
NYSE: LLY · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$934.60
+9.80% today
Updated 2026-04-30
Market cap
$760.43B
P/E ratio
37.03
P/S ratio
11.67x
EPS (TTM)
$22.99
Dividend yield
0.69%
52W range
$620 – $1,132
Volume
3.0M
Eli Lilly and Company (LLY) Financial statements
SEC filings — annual and quarterly data.
Profit margin
31.70%
Operating margin
44.90%
ROE
101.20%
ROA
19.40%
Debt/equity
1.60x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $15.69B | $2.66B | 77.40% | 26.29% | 16.97% |
| 2007 | $18.63B | $2.95B | 77.20% | 25.78% | 15.85% |
| 2008 | $20.37B | $-2.07B | 78.52% | 27.13% | -10.17% |
| 2009 | $21.84B | $4.33B | 80.55% | 29.17% | 19.82% |
| 2010 | $23.08B | $5.07B | 81.08% | 29.35% | 21.97% |
| 2011 | $24.29B | $4.35B | 79.13% | 26.01% | 17.90% |
| 2012 | $22.60B | $4.09B | 78.78% | 22.19% | 18.09% |
| 2013 | $23.11B | $4.68B | 78.76% | 24.00% | 20.27% |
| 2014 | $19.62B | $2.39B | 74.85% | 16.97% | 12.19% |
| 2015 | $19.96B | $2.41B | 74.76% | 18.00% | 12.07% |
| 2016 | $21.22B | $2.74B | 73.09% | 18.24% | 12.90% |
| 2017 | $19.97B | $-204.10M | 77.73% | 21.28% | -1.02% |
| 2018 | $21.49B | $3.23B | 78.22% | 28.04% | 15.04% |
| 2019 | $22.32B | $8.32B | 78.85% | 26.88% | 37.27% |
| 2020 | $24.54B | $6.19B | 77.66% | 29.38% | 25.24% |
| 2021 | $28.32B | $5.58B | 74.18% | 28.01% | 19.71% |
| 2022 | $28.54B | $6.24B | 76.77% | 30.32% | 21.88% |
| 2023 | $34.12B | $5.24B | 79.25% | 31.61% | 15.36% |
| 2024 | $45.04B | $10.59B | 81.31% | 38.86% | 23.51% |
| 2025 | $65.18B | $20.64B | 83.79% | 45.56% | 31.66% |